Friday 6 November 2026 Export HYFT’s income statement to Excel — free account

MindWalk Holdings Corp.

MindWalk Holdings Corp.’s revenue for fiscal 2026 (year ended April 2026) was $11.3 million, down 35.9% from fiscal 2025.

Revenue: +19.4%
EPS: −80.0%
Free cash flow: +9.79%
Total debt: −10.8%

Quarter to July 2026, against a year earlier

1.05 0.05 +5.00%

Follow HYFT

Alert me

Market cap: $47.1M
P/E: 0.0×
Fwd P/E: −3.9×
Dividend yield: —
F-score: 6/9
Altman Z: −5.59
Beneish M: −3.70
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 8.86%

Capital & Financial Ratios $m

Size

Market Cap 47.12

Revenue ttm 11.72

Net income ttm (12.31)

Free cash flow ttm (9.00)

Net debt Q (3.31)

Valuation

P/E 0.00

Forward P/E (3.85)

Price / sales 4.19

Forward P/S Powerpack

Price / FCF 0.00

Price / book 9.93

Financial health

Current ratio Q 1.84

Debt / equity Q 0.43

Interest coverage Q 720.73

Growth

Revenue growth Q +19.37%

Operating income growth Q −45.04%

EPS, this year −22.67%

EPS, next year A +14.00%

Revenue, next year A +11.26%

EPS, past 5 yrs —

EPS, next 5 yrs A +4.26%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 35.80%

10-year low 10-year high

P/B against its own 10 years 93.02%

10-year low 10-year high

EV/Sales against its own 10 years 39.97%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	3	8	8	5
Receivables	3	3	2	2
Inventory	2	2	0	0
Other	0	0	0	1
	9	13	12	9

	2024	2025	2026	Q'26
Payables	3	4	3	4
ST’ Debt	—	—	—	—
Other	0	0	—	—
	6	6	4	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	(3.83%)	(10.16%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(27.85%)	(41.94%)

Earnings Trends EPS, adjusted, against the consensus

Jul 2026 Estimate −0.05 Actual −0.09

−0.10 −0.08 −0.05 −0.02 0.00

Oct 2025 Miss −0.04

Jan 2026 Miss −0.02

Apr 2026 Miss −0.01

Jul 2026 Miss −0.04

Oct 2026 — Dec 21

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Oct 2025	−0.01	−0.05	Miss by 0.04
Jan 2026	−0.04	−0.06	Miss by 0.02
Apr 2026	−0.05	−0.06	Miss by 0.01
Jul 2026	−0.05	−0.09	Miss by 0.04
Oct 2026	−0.05	—	Reports 21 December 2026

EPS $

	Jul	Oct	Jan	Apr	Year
’26	(0.09)	—	—	—	—
’26	(0.05)	(0.05)	(0.06)	(0.06)	(0.22)
’25	(0.11)	(0.07)	(0.46)	(0.04)	(0.65)
’24	(0.11)	(0.07)	(0.08)	(0.52)	(0.78)
’23	(0.30)	(0.23)	(0.14)	(0.15)	(0.81)
’22	(0.14)	(0.21)	(0.16)	(0.17)	(0.67)
’21	(0.03)	(0.02)	(0.06)	(0.23)	(0.34)

Fiscal quarters ending in the months shown.

Revenue $m

	Jul	Oct	Jan	Apr	Year
’26	3	—	—	—	—
’26	2	3	3	3	11
’25	4	4	4	5	18
’24	4	5	5	5	18
’23	4	4	4	4	16
’22	4	4	4	4	15
’21	3	4	4	4	14

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jul	Oct	Jan	Apr	Year
’26	(3)	—	—	—	—
’26	(3)	(2)	(2)	(2)	(9)
’25	(1)	(2)	(1)	(1)	(5)
’24	(1)	0	0	(2)	(3)
’23	(8)	(3)	(3)	(2)	(15)
’22	(1)	(2)	(4)	(1)	(8)
’21	0	0	(1)	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jul	Oct	Jan	Apr	Year
’26	(3)	—	—	—	—
’26	(3)	(2)	(2)	(2)	(9)
’25	(2)	(2)	(1)	(1)	(5)
’24	(1)	0	0	(3)	(4)
’23	(8)	(3)	(3)	(2)	(16)
’22	(1)	(2)	(5)	(2)	(9)
’21	0	0	(1)	(2)	(2)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	TTM Jul ’26	Trend	10 yrs	2027e	2028e	2029e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	2	3	6	8	14	15	16	18	18	11	12		+21.6%	13	15	20	+20.1%
	Gross margin, %	27.33	(23.62)	(16.92)	(3.92)	64.41	56.72	55.95	49.16	55.25	58.80	60.81		+31.5 pt	Powerpack MindWalk Holdings Corp.’s next three years, line by line Analysts expect revenue to grow 20.1% a year to 2029 — slower than the 21.6% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(4)	(3)	(4)	(3)	(5)	(13)	(21)	(21)	(25)	(11)	(12)		+12.1%
	EBT margin, %	(207.80)	(93.02)	(69.67)	(37.65)	(33.47)	(81.84)	(134.29)	(117.07)	(139.75)	(99.96)	(106.43)		+107.8 pt
	Net income	0	(3)	(4)	(3)	(6)	(13)	(20)	(20)	(22)	(10)	(12)		n/m
Per share, $
Per share, $	Revenue	0.49	0.36	0.49	0.56	0.83	0.78	0.62	0.71	0.53	0.24	0.25		(7.5%)
	Earnings	(0.99)	(0.33)	(0.34)	(0.19)	(0.34)	(0.67)	(0.81)	(0.78)	(0.65)	(0.22)	(0.26)		(15.4%)
	Cash flow	(0.14)	(0.23)	(0.14)	(0.05)	(0.03)	(0.40)	(0.60)	(0.12)	(0.14)	(0.19)	(0.19)		+3.7%
	Capex	0.00	0.00	0.00	0.00	(0.06)	(0.05)	(0.05)	(0.04)	(0.02)	(0.01)	0.00		n/m
	Free cash flow	(0.14)	(0.23)	(0.14)	(0.05)	(0.09)	(0.45)	(0.64)	(0.16)	(0.15)	(0.20)	(0.19)		+4.1%
	Book value	0.57	0.84	0.80	0.57	2.64	3.05	1.75	0.98	0.51	0.18	0.11		(11.9%)
	Shares, m	4	9	13	14	16	20	25	26	33	46	46		+31.4%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	0.00	0.00	0.00	0.00	12.29	7.05	4.12	1.81	0.84	4.90	4.19		3.1
	P/B	0.00	0.00	0.00	0.00	3.89	1.81	1.47	1.31	0.87	6.48	9.93		1.6
	EV/Sales	0.00	0.00	0.00	0.00	10.16	5.59	4.05	2.19	1.00	4.56	4.10		2.8
	EV/FCF	0.00	0.00	0.00	0.00	(365.48)	(9.86)	(3.93)	(9.50)	(3.40)	(5.52)	(5.35)		(39.8)
Cash, $m
Cash, $m	Operating cash flow	(1)	(2)	(2)	(1)	0	(8)	(15)	(3)	(5)	(9)	(9)		+36.3%
	Capex	0	0	0	0	(1)	(1)	(1)	(1)	(1)	0	0		(3.3%)
	Free cash flow	(1)	(2)	(2)	(1)	(2)	(9)	(16)	(4)	(5)	(9)	(9)		+36.8%
Balance, $m
Balance, $m	Working capital	2	0	1	0	33	22	8	2	7	8	4		+17.3%
	Net debt	(2)	1	(1)	1	(29)	(23)	(2)	6	1	(6)	(3)		+13.7%
	Shareholders’ equity	2	8	10	8	44	60	43	25	17	9	5		+15.8%
Returns, %
Returns, %	ROA	(61,796.48)	(42.17)	(28.16)	(17.81)	(17.19)	(21.18)	(30.03)	(39.09)	(56.85)	(42.67)	(58.55)		+61,753.8 pt
	ROIC	0.00	0.00	0.00	0.00	(23.94)	(21.62)	(32.05)	(20.69)	(31.55)	(269.05)	(464.59)		(269.0) pt
	ROE	(381.82)	(63.01)	(48.75)	(29.87)	(21.87)	(25.72)	(38.62)	(58.67)	(103.12)	(79.38)	(122.85)		+302.4 pt
People
People	Employees	—	—	—	—	73	85	102	101	102	77	—		+1.1%
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.19	0.18	0.15	0.18	0.17	0.15	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Apr 2026 · latest quarter Jul 2026 · fundamentals updated 2 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HOWL Werewolf Therapeutics, Inc.	$49.6M	— (loss-making)	— (loss-making)	+256.11% (above 0%: growing)	n/m	+146.46% (above 0%: growing)	100.00%	34.09%	Compare
APLM Apollomics Inc.	$49.5M	— (loss-making)	—	—	0.00%	+76.08% (above 0%: growing)	—	—	Compare
TIL Instil Bio, Inc.	$47.4M	— (loss-making)	—	—	n/m	+68.62% (above 0%: growing)	0.00%	0.00%	Compare
IMA ImageneBio, Inc.	$47.3M	— (loss-making)	— (loss-making)	−60.08% (below 0%: shrinking)	n/m	+23.76% (above 0%: growing)	100.00%	0.00%	Compare
HYFT MindWalk Holdings Corp.	$47.1M	— (loss-making)	— (loss-making)	+19.37% (above 0%: growing)	n/m	+9.79% (above 0%: growing)	58.58%	(159.86%)
CNTB Connect Biopharma Holdings Limited Sponsored ADR	$46.1M	— (loss-making)	— (loss-making)	+296.56% (above 0%: growing)	n/m	−23.48% (below 0%: shrinking)	100.00%	(635.98%)	Compare
MREO Mereo BioPharma Group plc - Sponsored ADR	$44.8M	— (loss-making)	— (loss-making)	—	n/m	+21.02% (above 0%: growing)	0.00%	0.00%	Compare
IBIO iBio, Inc.	$44.4M	— (loss-making)	— (loss-making)	+100.00% (above 0%: growing)	n/m	−35.33% (below 0%: shrinking)	100.00%	0.00%	Compare
CRBU Caribou Biosciences, Inc.	$44.2M	— (loss-making)	— (loss-making)	−26.89% (below 0%: shrinking)	n/m	+84.78% (above 0%: growing)	100.00%	(1,720.10%)	Compare
Median of peers	$46.7M	—	—	+100.00%	—	+46.19%	100.00%	0.00%

All 621 Biotechnology stocks →

MindWalk Holdings Corp. (HYFT) Latest News

4 Nov

Impact 3 · 8:01 AM · Business Wire

MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows

21 Oct

Impact 4 · 8:01 AM · Business Wire

MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours

14 Oct

Impact 4 · 8:01 AM · Business Wire

MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies

6 Oct

Impact 4 · 8:46 AM · Business Wire

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function

1 Oct

Impact 3 · 8:46 AM · Business Wire

MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director

23 Sep

Impact 4 · 11:26 AM

MindWalk (HYFT) Is Pivoting to Recurring AI Revenue. Can ReefIQ Offset Widening Losses?

21 Sep

Impact 4 · 8:46 AM · Business Wire

MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine

15 Sep

Impact 4 · 10:01 AM · The Motley Fool transcript

MindWalk (HYFT) Q1 2027 Earnings Call Transcript

Impact 4 · 8:30 AM · Moby transcript

MindWalk Holdings Corp. Q1 2027 Earnings Call Summary

Impact 3 · 3:00 PM

MindWalk Holdings Corp (HYFT) (Q1 2027) Earnings Call Highlights: Revenue Climbs 21% as ReefIQ ...

14 Sep

Impact 4 · 4:56 PM

MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027

Impact 4 · 8:46 AM

MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion

Impact 3 · 6:05 PM

MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates

Impact 3 · 6:03 PM · MarketBeat transcript

MindWalk Q1 Earnings Call Highlights

24 Jul

Impact 4 · 9:10 AM

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed

23 Jul

Impact 3 · 4:02 PM

MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI

Impact 3 · 8:30 AM · Moby

MindWalk Holdings Corp. Q4 2026 Earnings Call Summary

Impact 3 · 1:00 AM

MindWalk Holdings Corp (HYFT) Q4 2026 Earnings Call Highlights: Strong Revenue Growth and ...

22 Jul

Impact 4 · 4:54 PM

MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure

15 Jul

Impact 3 · 8:45 AM

As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

6 Jul

Impact 3 · 8:30 AM

MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity

1 Jul

Impact 4 · 8:00 AM

MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery

10 Jun

Impact 4 · 9:16 AM · Business Wire

MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

2 Jun

Impact 3 · 7:20 AM · Business Wire

MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns

18 May

Impact 3 · 8:34 AM · Business Wire

The Biology Came First.

12 Mar

Impact 4 · 5:02 PM · GuruFocus.com

MindWalk Holdings Corp (HYFT) Q3 2026 Earnings Call Highlights: Revenue Surge and Strategic Shifts

Impact 4 · 12:39 PM · The Motley Fool transcript

MindWalk (HYFT) Q3 2026 Earnings Call Transcript

Impact 4 · 8:31 AM · Business Wire

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

Impact 3 · 12:44 PM · Moby

MindWalk Holdings Corp. Q3 2026 Earnings Call Summary

Impact 3 · 9:45 AM · Zacks

MindWalk Holdings Corp. (HYFT) Reports Q3 Loss, Lags Revenue Estimates

MindWalk Holdings Corp.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to April

MindWalk Holdings Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

MindWalk Holdings Corp. (HYFT) Latest News

4 Nov

21 Oct

14 Oct

6 Oct

1 Oct

23 Sep

21 Sep

15 Sep

14 Sep

24 Jul

23 Jul

22 Jul

15 Jul

6 Jul

1 Jul

10 Jun

2 Jun

18 May

12 Mar

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to April

MindWalk Holdings Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

MindWalk Holdings Corp. (HYFT) Latest News

4 Nov

21 Oct

14 Oct

6 Oct

1 Oct

23 Sep

21 Sep

15 Sep

14 Sep

24 Jul

23 Jul

22 Jul

15 Jul

6 Jul

1 Jul

10 Jun

2 Jun

18 May

12 Mar

Stockrow Weekly